Latest Articles
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Defense World
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Defense World
Published: March 2, 2026, 6:50 p.m.
Tampons could help early ovarian cancer diagnosis - AOL.com
Tampons could help early ovarian cancer diagnosis AOL.com
Published: March 2, 2026, 6:48 p.m.
GLP-1–Progestin and Endometrial Cancer Risk - Conexiant
GLP-1–Progestin and Endometrial Cancer Risk Conexiant
Published: March 2, 2026, 5:01 p.m.
Detecting the body's reproductive hormonal brake against tissue overgrowth: Micrin/SgII-70.
A new humoral factor has been detected, within a project aiming to disclose the body's reproductive hormonal brake against tissue overgrowth, micrin ('my-crin'). Factor purification involved fractionation of ovine and …
Published: March 2, 2026, midnight
Sarah Maree Cameron on cervical cancer, endometriosis and ADHD - bodyandsoul.com.au
Sarah Maree Cameron on cervical cancer, endometriosis and ADHD bodyandsoul.com.au
Published: Feb. 28, 2026, 9:25 p.m.
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon TipRanks
Published: Feb. 27, 2026, 7:47 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat
Published: Feb. 27, 2026, 4:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance
Published: Feb. 27, 2026, 4:47 p.m.
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval - TradingView
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval TradingView
Published: Feb. 27, 2026, 3:34 p.m.
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion - TradingView
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion TradingView
Published: Feb. 27, 2026, 2:50 p.m.
Link copied to clipboard!